U.S. drugmaker Pfizer's new $11 billion share repurchase plan is deflating expectations that it will make a new bid for AstraZeneca.» Read More
The bets against smaller biotech firms are usually stock specific, but the industry as a whole offers unique opportunities for short sellers.
Blackstone Advisory's Byron Wien still sees a 20 percent return for the S&P 500 for 2014, but he admits there are things that keep him up at night.
Propelled by Facebook and Twitter, the ice bucket challenge has become a viral sensation. Now Biogen executives and CNBC are rising to the challenge.
The FDA approved the first screening test for colon cancer that uses patients' DNA to help spot potentially deadly tumors and growths.
Is the world ready for genetically modified babies? Here's how close we really are, explains Jessica Cussins of the Center for Genetics and Society.
Tekmira Pharmaceutical's stocks have soared since the U.S. Food and Drug Administration cleared its experimental Ebola drug for human use.
Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its drug Lipitor.
Looking to trade on the Ebola scare? Ex-trader Turney Duff offers up what he'd do—and a word of caution.
The arrival of two U.S. Ebola patients and the testing of ill patients that recently traveled from West Africa have created fears. But are they genuine?
A lawsuit by Allergan says the unusual arrangement by Valeant Pharmaceuticals and activist investor Bill Ackman amounts to insider trading.
Sapphire glass and biotech companies are bringing out the bears ahead of this week's earnings.
The death toll from the Ebola virus in West Africa keeps growing to record levels. And ironically, that may be why there's no vaccine, said an expert.
Regulators are considering new rules to make pot-infused treats look different even when they're out of the packages.
West African leaders and international health groups have stepped up plans to combat the world’s worst outbreak of the deadly Ebola virus.
The US Peace Corps said it was withdrawing 340 volunteers from Liberia, Sierra Leone and Guinea due to the spreading Ebola virus across West Africa.
CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.
AstraZeneca took steps to build up its respiratory medicine business by striking a deal to acquire the rights to lung drugs developed by Almirall.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
Amgen posted higher-than-expected profit and said it would cut 12 to 15 percent of its workforce and close two plants.
Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.
Get the best of CNBC in your inbox